Forgot your password?

Forgot your username?

database > company
CardiAQ Valve Technologies
HCID Member | Medical Devices & Tech

Winchester, MA 01890 USA
phone:617-957-8945
fax:781-721-2798
Symbol Private
Founded 0
Employees 1
www.cardiaq.com
Research Sector Medical Devices & Tech
Summary Description
CardiAQ Valve Technologies (CVT) is developing innovative approaches to heart valve replacement and is initially focused on Transcatheter Mitral Valve Implantation (TMVI).
Management
J. Brent Ratz, Co-Founder, President and CEO; Arshad Quadri, MD, Founder; Chairman of the Board of Directors, cardiac surgeon, CMO; Joseph Bavaria, MD, Chairman, SAB; Rob Michiels, Director (former President/COO of CoreValve); Nancy Briefs, Director (President/CEO of Eleme Medical, 25+-year medtech industry veteran, successful serial entrepreneur).
Keywords
Mitral Regurgitation, Transcatheter Mitral Valve Implantation (TMVI)

Comment | Printable Version | Modify profile |
Updated: Oct. 11, 2010

Description
CardiaQ Valve Technologies is developing technologies for percutaneous mitral valve replacement to address the unmet needs of patients suffering from mitral regurgitation. No other heart valve company has a frame that is self-positioning, self-anchoring, and self-conforming in three dimensions. Consequently, CVTs technology has the unique potential to treat aortic stenosis, aortic regurgitation, and mitral regurgitation, says Joseph Bavaria, MD, Vice Chief, Cardiothoracic Surgery, Hospital of Pennsylvania; Professor of Surgery, UPenn. Dr. Bavaria also is a member of St. Jude Medicals Structural Heart Advisory Board, a Principal Investigator for the Edwards Lifesciences PARTNERtrial, and Chairman of CVTs Scientific Advisory Board. In vivo feasibility studies strongly suggest that CVTs TMVI approach may provide effective treatment of MR.
Products / Services
The initial focus of CVT's platform technology is Transcatheter Mitral Implantation (TMVI): designed to be an effective alternative to open-chest surgery for treating Mitral Regurgitation (MR).
Technology / Differentiation
There are more than two million people who suffer from Mitral Regurgitation (MR), yet only about 80,000 repair or replacement procedures take place each year. The significant treatment gap is largely due to the risk associated with the currently available surgical procedures. While several companies are attempting to develop percutaneous approaches to repair the mitral valve, these repair technologies have limited applicability due to the heterogeneous nature of the disease and, so far, have had a difficult time demonstrating efficacy that is equivalent to surgical approaches. Likewise, there are a number of technologies under development for catheter-based replacement of aortic valves. However, all of these technologies rely on radial force for fixation in heavily calcified leaflets, which is not suitable for the mitral position. CVTmay be the only company developing a transcatheter implantation approach to MR. CVTs unique anchoring and positioning technology platform allows the Company to compete where others cannot. As a result, CVT believes that its TMVI system will provide a faster, safer, and less-invasive alternative to traditional mitral valve surgery, while providing broader applicability and greater effectiveness than the other catheter-based technologies under development. With CVTs TMVI approach, a foldable tissue valve mounted on an expandable nitinol frame is delivered percutaneously via standard catheterization techniques and is implanted at the mitral valve annulus in a way that allows the native leaflets and subvalvular apparatus to remain intact.
Market / Customers
here are more than two million people who suffer from Mitral Regurgitation (MR), yet only about 80,000 repair or replacement procedures take place each year. The significant treatment gap is largely due to the risk associated with the currently available surgical procedures.
Competitors / Substitutes / Alternatives
While several companies are attempting to develop percutaneous approaches to repair the mitral valve, these repair technologies have limited applicability due to the heterogeneous nature of the disease and, so far, have had a difficult time demonstrating efficacy that is equivalent to surgical approaches. Likewise, there are a number of technologies under development for catheter-based replacement of aortic valves. However, all of these technologies rely on radial force for fixation in heavily calcified leaflets, which is not suitable for the mitral position.
Strategy
CVTmay be the only company developing a transcatheter implantation approach to MR. CVTs unique anchoring and positioning technology platform allows the Company to compete where others cannot.
Funding
CVT announced in May 2009 that it had received $750,000 in seed (translational) funding from Broadview Ventures Inc., which will be used to further develop CVT's platform with an initial indication for Transcatheter Mitral Valve Implantation (TMVI). Total funding in CVT is now $1.5 million.
Status
Privately held, seeking Series A funding.